As Hemmi notes: Some people will lose access. In an emailed statement to WIRED, a spokesperson for Novo Nordisk says, Moving forward, any compounder that mass produces or sells knockoff drugs is breaking the law and compromising patient safety. A spokesperson for Eli Lilly echoed that sentiment, saying via email that the FDA and a federal court have both made clear that compounders must cease production of compounded tirzepatide knockoffs. Anthony Comuzzie, CEO of the Obesity Society, recognizes that there are legitimate access issues to GLP-1 medications, but he worries that some people who have sought out compounded versions may not meet the medical definition of obesity and are using them more casually for weight loss
The combined reductions in cardiac output and peripheral vascular resistance ultimately lower systemic blood pressure (BP)
That shows the evidence base is still developing and still being monitored
The bacteria found on our skin consume sweat, semen, and urine, resulting in body odor
14% with placebo [75, 76]
A clear suitability assessment before treatment